<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364788">
  <stage>Registered</stage>
  <submitdate>19/08/2013</submitdate>
  <approvaldate>30/09/2013</approvaldate>
  <actrnumber>ACTRN12613001094763</actrnumber>
  <trial_identification>
    <studytitle>Risk Factors and Response to Therapy in Heart and Lung Transplant Patients with Posttransplant Lymphoproliferative Disease</studytitle>
    <scientifictitle>Risk Factors and Response to Therapy in Heart and Lung Transplant Patients with Posttransplant Lymphoproliferative Disease</scientifictitle>
    <utrn>Nil</utrn>
    <trialacronym>Nil</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Posttransplant Lymphoproliferative Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Observational study looking at factors which contribute to the risk of developing Post-transplant Lymphoproliferative Disease (PTLD) in heart and lung transplant patients as well as looking at what treatment was recieved and how this correlates to outcomes. Participants will be observed in a retrospective fashion from the time of diagnosis of PTLD until present</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival</outcome>
      <timepoint>Retrospective data collected from January 1984- January 2013</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse- Assessed by collection of data from patient records and haematology/transplant databases
</outcome>
      <timepoint>Retrospective data collected from January 1984- January 2013</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complications of treatment- Eg infection, mucositis, renal and hepatic toxicity. These measures are all assessed by collection of documented data from patient notes and from existing databases.</outcome>
      <timepoint>Retrospective data collected from January 1984-January 2013</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Transplant rejection episodes- Assessed by documented evidence of rejection from patient notes and existing databases</outcome>
      <timepoint>Retrospective data collected from January 1984-January 2013</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Heart and Lung transplant patients who were transplanted at St Vincent's Hospital, Sydney from the commencement of the transplant program until 2013.
Posttransplant lymphoproliferative disease was an inclusion criteria. No other malignant diseases were elligible.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Nil</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>Univariate and multivariate analysis</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2012</anticipatedstartdate>
    <actualstartdate>1/08/2012</actualstartdate>
    <anticipatedenddate>12/08/2013</anticipatedenddate>
    <actualenddate>12/08/2013</actualenddate>
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St Vincent's Hospital (Darlinghurst) - Darlinghurst</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>John Moore</primarysponsorname>
    <primarysponsoraddress>C/- Kinghorn Cancer Centre
      Department of Haematology
      Victoria Street
      Darlinghurst 2010 NSW</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>No funding</fundingname>
      <fundingaddress>N/A</fundingaddress>
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress>N/A</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This paper reports on the post-transplant lymphoproliferative disease (PTLD) experience of a single centre heart and lung transplant unit from its inception in 1984 to 2011 with respect to patient demographics, risk factors, management and outcomes. This detailed retrospective analysis aims to identify risk factors and describe outcomes in heart and lung transplant patients with PTLD to understand the unique clinical features of their disease in order to further develop tailored treatment strategies and prophylaxis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Orly Lavee</name>
      <address>c/- Sydney Children's Hospital
     Kids Cancer Centre
     High Street
     Randwick 2031 NSW</address>
      <phone>+61 (0)407906902</phone>
      <fax />
      <email>orly_l@hotmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Orly Lavee</name>
      <address>c/- Sydney Children's Hospital
     Kids Cancer Centre
     High Street
     Randwick 2031 NSW</address>
      <phone>+61 (0)407906902</phone>
      <fax />
      <email>orly_l@hotmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Orly Lavee</name>
      <address>c/- Sydney Children's Hospital
     Kids Cancer Centre
     High Street
     Randwick 2031 NSW</address>
      <phone>+61 (0)407906902</phone>
      <fax />
      <email>orly_l@hotmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Orly Lavee</name>
      <address>221 Storey Street
Maroubra NSW 2035</address>
      <phone>0407906902</phone>
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>